Ross
Well-known member
http://www.fda.gov/cder/Offices/ODS/MG/warfarinMG.pdf
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA and Bristol-Myers Squibb notified pharmacists and physicians of
revisions to the labeling for Coumadin, to include a new patient
Medication Guide as well as a reorganization and highlighting of the
current safety information to better inform providers and patients.
The FDA regulation 21CFR 208 requires a Medication Guide to be provided
with each prescription that is dispensed for products that FDA
determines pose a serious and significant public health concern.
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA and Bristol-Myers Squibb notified pharmacists and physicians of
revisions to the labeling for Coumadin, to include a new patient
Medication Guide as well as a reorganization and highlighting of the
current safety information to better inform providers and patients.
The FDA regulation 21CFR 208 requires a Medication Guide to be provided
with each prescription that is dispensed for products that FDA
determines pose a serious and significant public health concern.